文献速递类风湿关节炎脊柱关节炎

肿瘤坏死因子受体II参与FoxP3稳定性并作为类风湿关节炎中抗TNF治疗特异性扩增Treg细胞的标志物

Involvement of Tumor Necrosis Factor Receptor Type II in FoxP3 Stability and as a Marker of Treg Cells Specifically Expanded by Anti-Tumor Necrosis Factor Treatments in Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2020-02-20

该研究探讨表达肿瘤坏死因子受体II(TNFRII)的调节性T细胞(Treg)在实验模型中对炎症的控制及在类风湿关节炎(RA)或脊柱关节炎(SpA)患者抗TNF治疗反应中的作用。研究发现TNFRII表达识别出通过基因低甲基化稳定表达Foxp3的Treg亚群,且过继转移表达TNFRII的Treg可改善实验模型中的炎症;抗TNF治疗RA患者3个月时TNFRII+ Treg频率增加,而SpA患者未改变,提示TNFRII+ Treg的扩增和活化可能是抗TNF药物控制RA炎症的机制之一。

要点

  • TNFRII表达识别Foxp3基因低甲基化、稳定表达Foxp3的Treg亚群。
  • 过继转移表达TNFRII的Treg可减轻实验模型中的炎症。
  • 抗TNF治疗RA患者3个月时TNFRII+ Treg频率增加,SpA患者未改变。

核心结论

  • TNFRII表达识别出通过基因低甲基化稳定表达Foxp3的Treg亚群,过继转移表达TNFRII的Treg可改善实验模型中的炎症。
  • TNFRII+ Treg的扩增和活化可能是抗TNF药物控制RA炎症的机制之一,但在SpA中并非如此。

研究设计与样本

  • 采用多层面转化方法研究TNFRII在Treg细胞中的作用。
  • 通过亚硫酸氢盐测序分析Foxp3基因座甲基化状态评估Treg细胞稳定性。
  • 在TNFRII-/-小鼠中诱导咪喹莫特诱导的皮肤炎症和迟发型超敏反应性关节炎(DTHA)模型,伴或不伴过继转移野生型(WT)小鼠纯化的CD4+CD25+细胞。
  • 监测RA和SpA患者靶向治疗前后TNFRII+ Treg细胞群体的演变。

主要发现

  • TNFRII-/-小鼠Treg细胞中Foxp3基因甲基化程度高于WT小鼠(50% versus 36.7%)。
  • 在培养的Treg细胞中,TNF通过TNFRII信号增强Foxp3的表达、维持和增殖。
  • TNFRII-/-小鼠的咪喹莫特诱导的皮肤炎症和DTHA加重(皮肤炎症小鼠P < 0.05,DTHA踝关节肿胀小鼠P < 0.0001,与WT小鼠相比)。
  • 过继转移WT小鼠Treg细胞至TNFRII-/-小鼠可预防关节炎加重。
  • 接受抗TNF治疗的RA患者(而非接受托珠单抗者)治疗3个月时TNFRII+ Treg细胞频率较基线增加(均值±标准误 65.2 ± 3.1% versus 49.1 ± 5.5%;P < 0.01)。

临床怎么用

  • TNFRII+ Treg频率可能作为RA患者抗TNF治疗反应的潜在标志物。
  • 抗TNF治疗可能通过扩增和活化TNFRII+ Treg来控制RA炎症,而SpA中未见此变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the involvement of Treg cells expressing tumor necrosis factor receptor type II (TNFRII) in exerting control of inflammation in experimental models and in the response to anti-TNF treatments in patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA). METHODS: The role of TNFRII in Treg cells was explored using a multilevel translational approach. Treg cell stability was evaluated by analyzing the methylation status of the Foxp3 locus using bisulfite sequencing. Two models of inflammation (imiquimod-induced skin inflammation and delayed-type hypersensitivity arthritis [DTHA]) were induced in TNFRII-/- mice, with or without transfer of purified CD4+CD25+ cells from wild-type (WT) mice. In patients with RA and those with SpA, the evolution of the TNFRII+ Treg cell population before and after targeted treatment was monitored. RESULTS: Foxp3 gene methylation in Treg cells was greater in TNFRII-/- mice than in WT mice (50% versus 36.7%). In cultured Treg cells, TNF enhanced the expression, maintenance, and proliferation of Foxp3 through TNFRII signaling. Imiquimod-induced skin inflammation and DTHA were aggravated in TNFRII-/- mice (P < 0.05 for mice with skin inflammation and P < 0.0001 for mice with ankle swelling during DTHA compared to WT mice). Adoptive transfer of WT mouse Treg cells into TNFRII-/- mice prevented aggravation of arthritis. In patients with RA receiving anti-TNF treatments, but not those receiving tocilizumab, the frequency of TNFRII+ Treg cells was increased at 3 months of treatment compared to baseline (mean ± SEM 65.2 ± 3.1% versus 49.1 ± 5.5%; P < 0.01). In contrast, in anti-TNF-treated patients with SpA, the frequency of TNFRII+ Treg cells was not modified. CONCLUSION: TNFRII expression identifies a subset of Treg cells that are characterized by stable expression of Foxp3 via gene hypomethylation, and adoptive transfer of TNFRII-expressing Treg cells ameliorates inflammation in experimental models. Expansion and activation of TNFRII+ Treg cells may be one of the mechanisms by which anti-TNF agents control inflammation in RA, but not in SpA.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Santinon F, Batignes M, Mebrek ML, et al. Involvement of Tumor Necrosis Factor Receptor Type II in FoxP3 Stability and as a Marker of Treg Cells Specifically Expanded by Anti-Tumor Necrosis Factor Treatments in Rheumatoid Arthritis. Arthritis Rheumatol. 2020. PMID: 31609517. doi:10.1002/art.41134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。